TomoTherapy adds the TomoHD treatment system to its suite of advanced radiation therapy solutions

NewsGuard 100/100 Score

TomoTherapy Incorporated (NASDAQ: TOMO) today announced that it has extended its suite of advanced radiation therapy solutions with the addition of the TomoHD™ treatment system, an efficient, all-purpose new system designed to make it easier for any radiation oncology department to adopt TomoTherapy® technology for its patient population. The TomoHD treatment system will be introduced during the upcoming Annual Meeting of the American Society for Radiation Oncology (ASTRO), November 1-5, 2009, in Chicago.

Fully-featured to meet more needs
The new TomoHD treatment system bundles technologies previously available only as options for the TomoTherapy Hi·Art® system, as well as new core technologies. The result is a single comprehensive solution that efficiently handles both common and complex clinical indications with ease, broadening the possibilities for any radiation oncology practice and the patients it serves.

The TomoHD treatment system combines TomoHelical(SM) and TOMODIRECT(SM) delivery modes. The TomoHelical technique affords continuous 360-degree delivery for gold-standard treatment quality and targeting of complex volumes. The TomoDirect modality -- introduced in 2008 -- offers a discrete-angle delivery option, with 3D conformal radiation therapy (3DCRT) capabilities, for highly efficient treatment of more routine indications. In both delivery modes, clinicians follow the same basic process for planning, imaging and treating targets of up to 160 cm in length with no need to reposition the patient and no need for field junctioning. In addition to extended delivery versatility, the TomoHD treatment system comes complete with 1, 2.5 and 5 cm primary collimator settings that enable users to select the right beam slice width for each case, depending upon conformity and efficiency needs.

Source:

TomoTherapy

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
WOO Network trials investigate innovative treatments for liver, head and neck cancers